Brain Tumor Treatment Market Size was valued at USD 1.2 Billion in 2022. The Brain Tumor Treatment market industry is projected to grow from USD 1.34 Billion in 2023 to USD 3.38 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.20% during the forecast period (2023 - 2032). Growing on chemotherapies and increasing awareness and the high cost of treatment may hamper the market expansion of brain tumors, which are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
July 2024: Roche is enhancing personalized treatment options for brain tumor patients by utilizing advanced genomic profiling, thereby improving efficacy and reducing side effects.
June 2024: Novartis has introduced a CAR-T cell therapy targeting aggressive brain tumors like glioblastoma, showing promising results in early clinical trials.
May 2024: Merck has expanded its use of Keytruda, an immunotherapy drug, for treating certain brain tumors, showing it can effectively cross the blood-brain barrier and improve survival rates.
Precision medicine is transforming the landscape of Brain Tumor Treatment by tailoring therapies to individual patients based on their unique genetic and molecular profiles. Advances in genomic profiling and molecular diagnostics enable clinicians to identify specific mutations and biomarkers driving tumor growth, allowing for targeted therapies such as molecularly targeted drugs and immunotherapies. This trend reflects a shift towards personalized treatment approaches that maximize efficacy while minimizing side effects, ultimately improving patient outcomes in the Brain Tumor Treatment market. This factor drives the market CAGR.
Additionally, Multimodal treatment approaches are increasingly utilized in the management of brain tumors, combining surgery, radiation therapy, chemotherapy, and novel therapies such as targeted agents and immunotherapies. This trend underscores the importance of a comprehensive and multidisciplinary approach to treating brain tumors, aiming to maximize tumor control while preserving neurological function and quality of life for patients. Multimodal treatment strategies leverage the strengths of different modalities to overcome tumor heterogeneity and resistance mechanisms, leading to improved survival rates and long-term outcomes in the Brain Tumor Treatment market.
Minimally invasive techniques are gaining prominence in the Brain Tumor Treatment market, offering less invasive alternatives to traditional open surgeries. Procedures such as stereotactic radiosurgery, laser interstitial thermal therapy (LITT), and endoscopic surgery enable precise tumor targeting and removal while minimizing damage to surrounding healthy brain tissue. These techniques result in reduced post-operative morbidity, shorter hospital stays, and faster recovery times for patients. As advancements continue to improve the safety and efficacy of minimally invasive approaches, their adoption is expected to increase, shaping the future of Brain Tumor Treatment.
For instance, Bristol Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City, USA. Founded in 1858, BMS is one of the world's leading pharmaceutical companies, focusing on discovering, developing, and delivering innovative medicines for the treatment of serious diseases, including cancer, cardiovascular diseases, and immunological disorders. In June 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Board of Directors and is anticipated to close during the third quarter of 2022. Thus, driving the Brain Tumor Treatment market revenue.
The Brain Tumor Treatment market segmentation, based on Therapy, includes Targeted Therapy, Chemotherapy, Immunotherapy, and Others. The dominant category is Targeted Therapy, primarily due to its ability to selectively target cancer cells while sparing normal cells, resulting in fewer side effects and improved efficacy compared to conventional treatments. Meanwhile, the fastest-growing category is Immunotherapy, driven by advancements in harnessing the immune system to recognize and attack cancer cells. Immunotherapies such as immune checkpoint inhibitors and adoptive cell therapies have shown promising results in brain tumor patients, leading to increased adoption and research in this area.
Figure 1: Brain Tumor Treatment Market, by Therapy, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Brain Tumor Treatment market segmentation, based on Indication, includes Pituitary Tumors, Meningioma, Glioblastoma, and Others. The dominant category is Glioblastoma, owing to its aggressive nature and high incidence rate, making it one of the most common and challenging brain tumors to treat. Glioblastoma treatments often involve a combination of surgery, radiation therapy, and chemotherapy, reflecting the extensive research and clinical focus on this Indication. Meanwhile, the fastest-growing category is Pituitary Tumors, driven by increased detection rates and advancements in diagnostic imaging techniques. Pituitary tumors, while typically benign, can cause hormonal imbalances and neurological symptoms, prompting the development of targeted therapies and minimally invasive surgical techniques tailored to this Indication.
The Brain Tumor Treatment market segmentation, based on Distribution Channels, includes Hospital Pharmacy and Retail & Online Pharmacy. The dominant category is Hospital Pharmacy, primarily due to the complexity of Brain Tumor Treatments, which often require specialized medications, intravenous therapies, and close monitoring by healthcare professionals. Meanwhile, the fastest-growing category is Retail & Online Pharmacy, driven by the increasing availability of oral chemotherapy agents and supportive care medications for brain tumor patients. Retail and online pharmacies offer convenience and accessibility.
By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Brain Tumor Treatment market area will dominate this market, owing to an advanced healthcare infrastructure and a robust research and development ecosystem that drives innovation in brain tumor diagnosis and treatment. In addition, the growing number of established health clubs and fitness facilities will boost market growth in this region.
Further, the major countries studied in the market report are The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: BRAIN TUMOR TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Brain Tumor Treatment market accounts for the second-largest market share due to the well-established healthcare infrastructure with advanced medical facilities and a skilled workforce specializing in neuro-oncology. Further, the German Brain Tumor Treatment market held the largest market share, and the UK Brain Tumor Treatment market was the fastest-growing market in the European region.
The Asia-Pacific Brain Tumor Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to the increasing disease burden that creates a significant demand for Brain Tumor Treatment options and therapies in the Asia-Pacific region. Moreover, China’s Brain Tumor Treatment market held the largest market share, and the Indian Brain Tumor Treatment market was the fastest-growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Brain Tumor Treatment market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Brain Tumor Treatment industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Brain Tumor Treatment industry to benefit clients and increase the market sector. In recent years, the Brain Tumor Treatment industry has offered some of the most significant advantages. Major players in the Brain Tumor Treatment market include F. Hoffmann-La Roche Ltd (U.S.), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), NextSource Pharmaceuticals, LLC (U.S.), Emcure Pharmaceuticals (India), Siemens Healthineers AG, Dr. Reddy’s Laboratories Ltd., and others are attempting to increase market demand by investing in research and development operations.
Bristol Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City, USA. Established in 1858, BMS has evolved into one of the world's leading pharmaceutical firms, dedicated to discovering, developing, and delivering innovative medicines to address significant unmet medical needs, particularly in oncology, immunology, cardiovascular, and fibrosis. In June 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously approved by both the Bristol Myers Squibb and Turning Point Therapeutics Board of Directors and is anticipated to close during the third quarter of 2022.
Pfizer Inc. is a leading American multinational pharmaceutical corporation headquartered in New York City, USA. Established in 1849, Pfizer has grown to become one of the largest pharmaceutical companies globally, with a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products. In August 2022, American drug maker Pfizer announced a deal to acquire Global Blood Therapeutics, makers of a recently approved treatment for sickle cell disease, for US$ 5.4 billion.
Key Companies in the Brain Tumor Treatment Market Include
Brain Tumor Treatment Industry Developments
June 2022: Novartis AG's medicine lapatinib helped reduce brain tumors in patients with a type of lung cancer in a mid-stage study. New data has shown that the drug benefited a subset of patients who had brain metastases in which tumors develop away from the initial site of cancer.
April 2020:F. Hoffmann-La Roche Ltd. received Health Canada approval for its drug Rozlytrek (entrectinib) for adult patients with locally advanced or metastatic extracranial solid tumors, including brain metastases.
| Report Attribute/Metric | Details |
| Market Size2022 | USD 1.2 Billion |
| Market Size 2023 | USD 1.34 Billion |
| Market Size2032 | USD 3.38 Billion |
| Compound Annual Growth Rate (CAGR) | 12.20% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Therapy, Indication, Distribution Channel and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd (U.S.), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.),Amgen Inc. (U.S.), NextSource Pharmaceuticals, LLC (U.S.), Emcure Pharmaceuticals (India), Siemens Healthineers AG, Dr. Reddy's Laboratories Ltd |
| Key Market Opportunities | · Growing on chemotherapies and increasing awareness |
| Key Market Dynamics | · The high cost of treatment may hamper the market expansion of the brain tumor. |
Frequently Asked Questions (FAQ) :
The Brain Tumor Treatment market size was valued at USD 1.2 Billion in 2022.
The global market is projected to grow at a CAGR of 12.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are F. Hoffmann-La Roche Ltd (U.S.), Novartis AG (Switzerland), Merck& Co. Inc. (U.S.), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.),Amgen Inc. (U.S.), NextSource Pharmaceuticals, LLC (U.S.), Emcure Pharmaceuticals (India), Siemens Healthineers AG, and Dr. Reddy's Laboratories Ltd.
The Targeted Therapy category dominated the market in 2022.
The Glioblastoma segment had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
